Vericel Corporation stock rating and score history
All changes in ratings, performance and outlook tracked over time.
Vericel Corporation stock price, chart patterns and momentum
Recent price movements, trend behaviour and momentum signals based on real-time market data.
What does Vericel Corporation do? Business model and key facts
Get the full picture of Vericel Corporation: what it builds, where it operates, and how it makes money.
Sector: Healthcare
Industry: Biotechnology
Employees (FY): 357
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns. Its preapproval stage product is NexoBrid, a registration-stage biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.
Stocks related to Vericel Corporation
Selected based on industry alignment and relative market positioning.
Events and news impacting Vericel Corporation stock
Earnings, coporate decisions and industry developments that can affect the share price.
Vericel Corporation fundamentals and technical analysis
Financial fundamentals and technicals signals combined to access stability, momentum and market direction.
